Inovio Pharmaceuticals (NASDAQ:INO) Hit With Buy Rating From Citigroup, Analysts Expect $10.0 Stock Price

December 7, 2017 - By Marguerite Chambers

 Inovio Pharmaceuticals (NASDAQ:INO) Hit With Buy Rating From Citigroup, Analysts Expect $10.0 Stock Price

Why Has Citigroup Given Inovio Pharmaceuticals (NASDAQ:INO) a $10.0 Price Target

In an analyst report revealed today, Citigroup analysts began Inovio Pharmaceuticals (NASDAQ:INO) coverage with Buy rating, and a $10.0 PT.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Ratings Coverage

Among 8 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals has $31 highest and $9 lowest target. $14.33’s average target is 227.17% above currents $4.38 stock price. Inovio Pharmaceuticals had 34 analyst reports since August 10, 2015 according to SRatingsIntel. H.C. Wainwright maintained Inovio Pharmaceuticals, Inc. (NASDAQ:INO) on Friday, July 7 with “Buy” rating. Zacks downgraded the shares of INO in report on Friday, August 14 to “Hold” rating. The rating was maintained by Stifel Nicolaus on Tuesday, August 8 with “Buy”. The rating was maintained by Maxim Group on Wednesday, September 9 with “Buy”. PiperJaffray downgraded Inovio Pharmaceuticals, Inc. (NASDAQ:INO) rating on Thursday, March 16. PiperJaffray has “Neutral” rating and $9 target. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, August 9 report. The firm has “Buy” rating given on Thursday, November 9 by H.C. Wainwright. Aegis Capital maintained the stock with “Buy” rating in Thursday, June 1 report. The rating was maintained by Aegis Capital on Thursday, June 8 with “Buy”. Maxim Group maintained the stock with “Buy” rating in Tuesday, January 5 report.

It closed at $4.38 lastly. It is down 29.01% since December 7, 2016 and is downtrending. It has underperformed by 45.71% the S&P500.

Analysts await Inovio Pharmaceuticals, Inc. (NASDAQ:INO) to report earnings on March, 21. They expect $-0.29 EPS, up 19.44 % or $0.07 from last year’s $-0.36 per share. After $-0.40 actual EPS reported by Inovio Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -27.50 % EPS growth.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company has market cap of $395.50 million. The Company’s SynCon immunotherapy design has the ability to break the immune systemÂ’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It currently has negative earnings. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus.

More recent Inovio Pharmaceuticals, Inc. (NASDAQ:INO) news were published by: Fool.com which released: “Why Inovio Pharmaceuticals Inc. Is Sinking Today” on November 09, 2017. Also Globenewswire.com published the news titled: “Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors” on December 06, 2017. Globenewswire.com‘s news article titled: “Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with …” with publication date: November 27, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.